Seoul National University Bundang Hospital (SNUBH)
Liver cancer stage 2 treatment cost in South Korea typically includes a consultation with an oncologist ranging from AUD $42 to AUD $139 and essential imaging like an abdominal CT scan for AUD $833 to AUD $1,249. Total expenses depend on the surgical approach, hospital tier, and specific drug protocols. Patients generally save 30–60% compared to private costs in Australia or the United States. Top treatment centres are located in Seoul.
Typical Liver Cancer Stage 2 Treatment Costs in South Korea
Bookimed Expert Insight: Patients seeking high-precision interventions should consider Korea University Anam Hospital. It performed the first successful robotic surgery for certain cancer stages in Asia. For complex cases, Seoul National University Hospital (SNUH) provides the highest cancer treatment statistics in the country. It is the preferred facility for the South Korean President. Larger centres like Asan Medical Center manage over 180,000 patients annually, demonstrating routine expertise in handling difficult diagnoses.
| Republic of Korea | Thailand | Turkey | |
| Chemotherapy for breast cancer | from AUD $26,643 | from AUD $4,163 | from AUD $1,665 |
| Radiation therapy for colorectal cancer | - | from AUD $7,632 | from AUD $9,714 |
No hidden fees – just official clinic prices. Pay at the clinic for Liver cancer stage 2 treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Liver cancer stage 2 treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Liver cancer stage 2 treatment journey.
Professor Lee Seok-gu is a leading liver transplant surgeon at Myongji Hospital. He has performed about 2,000 liver transplants. He achieved Korea’s first transfusion-free liver transplant. He performed hepatocyte transplantation in a one-month-old infant. He led the first clinical use of a bioartificial liver for acute liver failure. He also performed living-donor transplants in Egypt and trained teams in Vietnam.
He is Professor of Surgery at Myongji Hospital and former Director of the Organ Transplantation Center at Samsung Medical Center. He earned his MD and MSc from Seoul National University and his PhD from the Catholic University of Korea. He completed a fellowship at Boston Children’s Hospital/Harvard and transplant training at Johns Hopkins. He served as president of three national societies in transplantation and pediatric surgery. His honors include the Chong Kun Dang Award, the Pfizer Clinical Medicine Award, and the Astellas Investigator Award. He has 447 publications and 13 book chapters.
Republic of Korea reports a 71.3% 5-year survival rate for localised liver cancer, such as stage 2. Advanced medical centres achieve even higher results. For instance, Asan Medical Center maintains a 98% success rate for liver transplants. This rate is for complex cases.
Bookimed Expert Insight: Quality of care in Seoul is exceptionally high because surgeons handle massive patient volumes. Asan Medical Center alone performs over 65,000 surgeries per year. This deep experience often leads to better results for stage 2 cases. These results surpass standard Western benchmarks. Many top Korean clinics also hold JCI or GHA accreditation. This makes them highly suitable for Australian patients.
Patient Consensus: Patients in Republic of Korea emphasise that survival stats are a broad average. Many find that seeking second opinions at experienced centres leads to better individual results. They note that personal health, immune status, and the specialised team's experience are more important. These factors matter more than general figures.
Curative surgical resection is the main treatment for stage 2 liver cancer in South Korea. This procedure removes the tumour and surrounding healthy tissue while preserving liver function. Specialists prioritise surgery for patients with well‑preserved liver health and limited tumour spread.
Bookimed Expert Insight: South Korean oncology centres lead the world in transplant and laparoscopic innovation. Asan Medical Center performs the highest number of transplants in Korea. Seoul National University Bundang Hospital pioneered the first laparoscopic liver resection in a child. This high surgical volume means Korean specialists stay expert in complex cases that might be considered inoperable elsewhere.
Patient Consensus: Patients in the Republic of Korea stress that hospitals often repeat scans rather than relying on previous medical records. They suggest asking about systemic therapies such as lenvatinib if local treatments like TACE do not control the tumour.
South Korean hospitals treat stage 2 liver cancer with cirrhosis using a multidisciplinary approach. Specialists prioritise liver transplants or laparoscopic resections based on Child-Pugh scores. Major Seoul centres hold JCI accreditation and report a 98% liver transplant success rate for complex cases.
Bookimed Expert Insight: Data shows a massive experience gap in Seoul. Asan Medical Center performs over 55,000 surgeries yearly. Seoul National University Hospital has completed 1,000+ liver transplants. Australian patients should target these high-volume centres. Their immense caseload leads to higher success rates in managing tumours alongside cirrhosis.
Patient Consensus: Patients note that doctors decide treatment based on liver function and tumour location rather than stage alone. They suggest acting quickly to secure specialist appointments in Korea. Timing is critical while cirrhosis impacts stability.
Radiofrequency ablation (RFA) is available in South Korea for stage 2 liver cancer. Major Seoul centres use ultrasound-guided systems to treat tumours. This non-surgical method suits lesions up to 5 cm. Specialists often combine RFA with other therapies to improve outcomes for intermediate-stage cases.
Bookimed Expert Insight: South Korean university hospitals maintain some of the highest liver treatment volumes globally. Seoul National University Hospital treats 30,000 international patients annually. It reports a 90% success rate in its radiosurgery centre. This high volume means interventional radiologists handle complex stage 2 cases frequently. They often use no-touch RFA techniques. This specific approach creates larger, more effective ablation zones around the tumour. This reduces local progression.
Patient Consensus: Patients find RFA straightforward with minimal side effects like temporary soreness or fatigue. They note that eligibility depends strictly on tumour location and size. Those treated in Seoul appreciate the quick recovery compared to traditional surgery. They also appreciate the availability of 24/7 interpreters.
South Korea uses world-leading technology for stage 2 liver cancer treatment. Major Seoul-based centres specialise in curative approaches like laparoscopic surgery, proton beam therapy, and TARE. Most hospitals hold JCI or KOIHA accreditation. This means they meet international standards for patient safety and clinical quality.
Bookimed Expert Insight: South Korea's high surgical volumes directly improve outcomes for stage 2 cases. Asan Medical Center performs over 65,000 surgeries annually. Severance Hospital manages 40,000 operations. This massive scale allows surgeons to specialise in specific liver resection techniques. These techniques are less common in smaller medical systems.
Patient Consensus: Patients value how quickly Korean hospitals organise tests, biopsies, and consultations. They note the system is well-equipped with current imaging and multidisciplinary teams. They also suggest confirming whether a hospital offers specific multidisciplinary liver care, rather than general oncology.
Stage 2 liver cancer follow-up in Korea centres on intensive surveillance to catch recurrence early. Patients usually attend check-ups every 3 to 6 months for the first 2 years. These visits happen at JCI-accredited Seoul hospitals. They involve contrast-enhanced CT or MRI scans paired with Alpha-foetoprotein blood tests.
Bookimed Expert Insight: General guidelines suggest 3 to 6-month intervals. However, Korea's high-volume centres like Asan Medical Center often maintain tighter schedules for stage 2 cases. These centres handle over 65,000 surgeries yearly. They report a 98% success rate for liver transplants. This high patient turnover means their oncology teams have refined protocols. These protocols identify subtle recurrence patterns earlier than standard international guidelines might require.
Patient Consensus: Patients note that Korean doctors focus heavily on blood work and liver function tests. These are done alongside scans. They appreciate that follow-up intervals only increase to 6 or 12 months. This happens once the cancer remains stable over several years.
South Korea offers numerous clinical trials for stage 2 liver cancer. These include combination immunotherapies and natural killer cell therapies. Leading JCI-accredited Seoul hospitals frequently conduct studies to address intermediate and advanced tumours. These trials often focus on combining standard chemotherapy with radiation or innovative cell therapies.
Bookimed Expert Insight: While many search for trials, Korea's standard liver treatments are exceptionally high-performing. Asan Medical Center reports a 98% liver transplant success rate. Seoul National University Hospital has completed over 1,000 liver transplants. Patients should consider whether these established protocols provide more predictable outcomes than early-phase experimental trials.
Patient Consensus: Patients note that eligibility for Korean trials depends heavily on exact tumour details. It also depends on prior treatment history. Many advise confirming if a centre accepts international patients. This is important for specific phase 1 or 2 oncology studies.